Safety and Performance Evaluation of a New Catheter Range for Lead Implantation At Interventricular Septum

Inclusion criteria (phase I): * Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC) * Patient planned for a de novo implantation of any Single Chamber (SR) or Dual Chamber (DR) CE marked pacemaker * Patient planned for a catheter-guided implantation in the interventricular septum area * Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter * Patient reviewed, signed and dated the Informed Consent Form (ICF) Inclusion criteria (phase II): * Patient indicated for cardiac pacing or CRT according to the most recent guidelines from the ESC * Patient planned for a de novo implantation of any SR or DR CE marked pacemaker, or any CE marked CRT-D * Patient planned for a catheter-guided implantation in the interventricular septum area * Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter * Patient reviewed, signed and dated the ICF Exclusion criteria (phase I): * Patient planned for a device upgrade, or a device or a lead replacement * Patient with a congenital heart disease * Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy * Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35% * Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device) * Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery) * Minor age patient (i.e. under 18 years of age) * Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation * Non-menopausal women Exclusion criteria (phase II): * Patient planned for a device upgrade, or a device or a lead replacement * Patient with a congenital heart disease * Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy * Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device) * Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery) * Minor age patient (i.e. under 18 years of age) * Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation * Non-menopausal women